Rapid Expansion of Highly Functional Antigen-Specific T Cells from Patients with Melanoma by Nanoscale Artificial Antigen-Presenting Cells.


Journal

Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500

Informations de publication

Date de publication:
01 07 2020
Historique:
received: 23 10 2019
revised: 13 02 2020
accepted: 30 03 2020
pubmed: 4 4 2020
medline: 15 9 2021
entrez: 4 4 2020
Statut: ppublish

Résumé

Generation of antigen-specific T cells from patients with cancer employs large numbers of peripheral blood cells and/or tumor-infiltrating cells to generate antigen-presenting and effector cells commonly requiring multiple rounds of restimulation Nano-aAPC-expressing HLA-A*0201 molecules and costimulatory anti-CD28 antibody and HLA-A*0201 molecules loaded with MART-1 or gp100 class I-restricted peptides were used to stimulate CD8 T cells purified from the peripheral blood of treatment-naïve or PD-1 antibody-treated patients with stage IV melanoma. Expanded cells were restimulated with fresh peptide-pulsed nano-aAPC at day 7. Phenotype analysis and functional assays including cytokine release, cytolysis, and measurement of avidity were conducted. MART-1-specific CD8 T cells rapidly expanded up to 1,000-fold by day 14 after exposure to peptide-pulsed nano-aAPC. Expanded T cells had a predominantly stem cell memory CD45RA Peptide-pulsed nano-aAPC rapidly expanded polyfunctional antigen-specific CD8 T cells with high avidity, potent lytic function, and a stem cell memory phenotype from patients with melanoma.

Identifiants

pubmed: 32241816
pii: 1078-0432.CCR-19-3487
doi: 10.1158/1078-0432.CCR-19-3487
pmc: PMC7334099
mid: NIHMS1582183
doi:

Substances chimiques

Antigens, Neoplasm 0
Biomarkers 0
Cytokines 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

3384-3396

Subventions

Organisme : NCI NIH HHS
ID : R33 CA229042
Pays : United States
Organisme : NCI NIH HHS
ID : R00 CA230201
Pays : United States
Organisme : NIBIB NIH HHS
ID : P41 EB028239
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA175732
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007057
Pays : United States
Organisme : NCI NIH HHS
ID : K99 CA230201
Pays : United States

Informations de copyright

©2020 American Association for Cancer Research.

Références

Nat Biotechnol. 2018 Feb;36(2):160-169
pubmed: 29334370
J Exp Med. 2016 Jun 27;213(7):1133-9
pubmed: 27242164
J Immunother. 2003 Sep-Oct;26(5):440-50
pubmed: 12973033
Cytotherapy. 2009;11(7):912-22
pubmed: 19903103
N Engl J Med. 2008 Jun 19;358(25):2698-703
pubmed: 18565862
Small. 2015 Apr;11(13):1519-25
pubmed: 25641795
Nat Med. 2016 Apr;22(4):433-8
pubmed: 26901407
Science. 2015 May 15;348(6236):803-8
pubmed: 25837513
Front Immunol. 2018 Nov 28;9:2798
pubmed: 30546367
Mol Ther Methods Clin Dev. 2014 Mar 05;1:14001
pubmed: 26015949
Clin Exp Immunol. 2011 Jan;163(1):1-10
pubmed: 20964638
Immunol Rev. 2014 Jan;257(1):250-63
pubmed: 24329802
Int Immunol. 2010 Nov;22(11):863-73
pubmed: 21059769
J Clin Invest. 2016 Sep 1;126(9):3363-76
pubmed: 27482888
Cancer Immunol Immunother. 2012 Feb;61(2):289-293
pubmed: 22237887
Nat Med. 2001 Oct;7(10):1159-62
pubmed: 11590442
Haematologica. 2008 Oct;93(10):1523-34
pubmed: 18728033
ACS Nano. 2015 Jul 28;9(7):6861-71
pubmed: 26171764
Cancer Res. 2008 Apr 15;68(8):3010-8
pubmed: 18413771
Oncoimmunology. 2012 Mar 1;1(2):172-178
pubmed: 22720238
Nat Med. 2017 Jan 6;23(1):18-27
pubmed: 28060797
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
J Immunol. 2017 May 1;198(9):3507-3514
pubmed: 28341670
Science. 2014 Dec 19;346(6216):1536-40
pubmed: 25525252
Biomaterials. 2017 Feb;118:16-26
pubmed: 27940380
Mol Immunol. 2009 Feb;46(5):893-901
pubmed: 19041139
Nanomedicine. 2014 Jan;10(1):119-29
pubmed: 23891987
J Transl Med. 2010 Oct 26;8:104
pubmed: 20977748
Clin Cancer Res. 2011 Aug 15;17(16):5343-52
pubmed: 21737507
J Immunol. 2003 Sep 1;171(5):2251-61
pubmed: 12928369
Clin Cancer Res. 2006 May 15;12(10):2967-75
pubmed: 16707591
Curr Opin Immunol. 2017 Apr;45:43-51
pubmed: 28192720
Nat Med. 2003 May;9(5):619-24
pubmed: 12704385
Sci Transl Med. 2013 Feb 27;5(174):174ra27
pubmed: 23447018
Nat Nanotechnol. 2014 Aug;9(8):639-47
pubmed: 25086604
J Immunol Methods. 2005 Jul;302(1-2):145-55
pubmed: 15992809
Clin Cancer Res. 2010 May 1;16(9):2646-55
pubmed: 20406835
Curr Opin Immunol. 2009 Apr;21(2):233-40
pubmed: 19304471
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
Semin Cancer Biol. 2012 Aug;22(4):298-306
pubmed: 22414911
Cancer Immunol Immunother. 2008 Feb;57(2):175-83
pubmed: 17657490
J Immunol. 1999 Feb 15;162(4):2227-34
pubmed: 9973498
J Immunol. 2010 Jan 1;184(1):452-65
pubmed: 19949105
Adv Mater. 2019 Jun;31(23):e1807359
pubmed: 30968468
J Immunother. 2009 Feb-Mar;32(2):169-80
pubmed: 19238016
Nat Protoc. 2014 Apr;9(4):950-66
pubmed: 24675735
Lancet Oncol. 2016 Jul;17(7):943-955
pubmed: 27269740
Clin Cancer Res. 2007 Mar 15;13(6):1857-67
pubmed: 17363542
J Biol Chem. 2011 Oct 7;286(40):34883-92
pubmed: 21849500
J Immunother. 2013 Feb;36(2):133-51
pubmed: 23377668
J Immunol. 2012 Mar 1;188(5):2102-10
pubmed: 22291187
Cancer Immunol Immunother. 2004 Jun;53(6):510-8
pubmed: 14740176
Blood. 2013 Aug 8;122(6):863-71
pubmed: 23770775
Blood. 2006 Feb 15;107(4):1528-36
pubmed: 16239433
Nat Biotechnol. 2015 Jan;33(1):64-72
pubmed: 25485616
Nat Med. 2000 Dec;6(12):1406-10
pubmed: 11100129
Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3669-74
pubmed: 20133680
Science. 2015 Apr 3;348(6230):62-8
pubmed: 25838374
Nat Biotechnol. 2002 Feb;20(2):143-8
pubmed: 11821859
ACS Chem Biol. 2015 Feb 20;10(2):485-92
pubmed: 25372624

Auteurs

Junya Ichikawa (J)

NYU Langone Medical Center, Laura and Isaac Perlmutter Cancer Center, New York, New York. junya.ichikawa@nyulangone.org jeffrey.weber@nyulangone.org.

Tatsuya Yoshida (T)

NYU Langone Medical Center, Laura and Isaac Perlmutter Cancer Center, New York, New York.

Ariel Isser (A)

Johns Hopkins School of Medicine, Baltimore, Maryland.

Andressa S Laino (AS)

NYU Langone Medical Center, Laura and Isaac Perlmutter Cancer Center, New York, New York.

Melinda Vassallo (M)

NYU Langone Medical Center, Laura and Isaac Perlmutter Cancer Center, New York, New York.

David Woods (D)

NYU Langone Medical Center, Laura and Isaac Perlmutter Cancer Center, New York, New York.

Sojung Kim (S)

NexImmune Inc., Gaithersburg, Maryland.

Mathias Oelke (M)

NexImmune Inc., Gaithersburg, Maryland.

Kristi Jones (K)

NexImmune Inc., Gaithersburg, Maryland.

Jonathan P Schneck (JP)

Johns Hopkins School of Medicine, Baltimore, Maryland.

Jeffrey S Weber (JS)

NYU Langone Medical Center, Laura and Isaac Perlmutter Cancer Center, New York, New York. junya.ichikawa@nyulangone.org jeffrey.weber@nyulangone.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH